Skip to content

Maria De Lourdes Bastos

REQUIMTE, Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.

3 papers in the library · 130 citations · publishing 2004-2014

Papers

Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human.

Toxicology January 5, 2005 Helena Carmo, Jan G Hengstler, Douwe De Boer et al. 85 citations

The psychoactive designer drug 2C-B is broken down by liver cells from humans, monkeys, dogs, rabbits, rats, and mice through oxidative deamination and demethylation, producing several metabolites. A previously unknown metabolite, 4-bromo-2,5-dimethoxy-phenol (BDMP), appeared only in mouse cells, while another metabolite, 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), formed in human, monkey, and rabbit cells but not in dog, rat, or mouse cells. Toxic effects on liver cells varied little across species but showed large differences among cells from three human donors, indicating that individual human variation may be more important than species differences in determining 2C-B toxicity.

Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences November 25, 2004 Helena Carmo, Douwe De Boer, Fernando Remião et al. 32 citations

The psychoactive drug 2C-B, sold as 'Ecstasy', is metabolized in mice, producing several metabolites detectable in urine by GC/MS. Unchanged 2C-B and these metabolites were identified, providing data that may help understand the drug's biological and toxicological effects and aid forensic analysis of samples from human abusers.

Analytical investigation of legal high products containing Salvia divinorum traded in smartshops and internet.

Forensic science international September 1, 2014 Fernando Xavier Moreira, Félix Carvalho, Maria De Lourdes Bastos et al. 13 citations

Products containing the hallucinogenic plant Salvia divinorum, sold legally in smartshops and online, often mislead consumers about their potency and composition. Analysis of 10 such products, labeled with potencies from 5x to 60x, found that salvinorin A was the primary hallucinogen, along with three related compounds. Labeled concentrations of salvinorin A frequently did not match the actual amounts, and the true concentrations far exceeded the level needed to produce hallucinogenic effects. Safety information was often omitted, encouraging recreational use without adequate warnings.